Author and publication year | Study design, settings, and year | Sex | Mean age (years) | Matched mean age (years) | HIV status | Hypertension definition criteria used for MetS estimate | MetS definition criteria | |||
---|---|---|---|---|---|---|---|---|---|---|
HIV+ | HIV− | HIV+ | HIV− | |||||||
1 | Amusa et al., 2016 [33] | Cross sectional, Nigeria, NS | Both | 41 ± 7/40 ± 8 α | 41 ± 7 | 40 ± 8 | 150 | 50 | Not stated | Other |
2 | Ayodele et al., 2012 [32] | Cross sectional, Nigeria, NS | Both | 39.5–9.3 | NA | NA | 291 | NA | ≥ 130/85 and on antihypertensive treatment | IDF, ATP, JIS |
3 | Berhane et al., 2012 [34] | Cross-sectional, Ethiopia, 2010 | Both | 18 and above | NA | NA | 313 | NA | ≥140/90 and on antihypertensive treatment | ATP |
4 | Tesfaye et al., 2014 [42] | Cross sectional, Ethiopia, 2012–13 | Both | 32.7 ± 9.7 (ART) 32.6 ± 7.8 (naïve) | NA | NA | 374 | NA | ≥ 130/85 and on antihypertensive treatment | IDF, ATP |
5 | Sobieszczyk et al., 2016 [29] | Cross-sectional, South Africa, 2013 | Female | Median 24 years | NA | NA | 160 | NA | ≥ 130/85 and on antihypertensive treatment | ATP |
6 | Obirikorang et al., 2016 [41] | Cross sectional, Ghana,2013 | Both | 40.3 ± 0.8 | NA | NA | 433 | NA | ≥ 130/85 and on antihypertensive treatment | IDF, ATP, WHO |
7 | Ngatchou et al., 2013 [40] | Cross sectional, Cameroon, 2009–10 | Both | 41 ± 12α/39 ± 10 | 39.0 ± 10.0 | 41 ± 12 | 108 | 96 | ≥ 140/90 and on antihypertensive treatment | IDF |
8 | Fourie et al., 2010 [35] | Case control, South Africa, 2005 | Both | 44 ± 7.81α/44 ± 8.04 | 44.0 ± 8.04 | 44.0 ± 7.81 | 300 | 300 | ≥ 130/85 and on antihypertensive treatment | IDF, ATP |
9 | Muhammad et al., 2013 [45] | Cross sectional, Nigeria, 2009 | Both | 32.5 ± 7.55 | NA | NA | 200 | NA | ≥ 140/90 and on antihypertensive treatment | IDF |
10 | Mbunkah et al., 2014 [38] | Cross sectional, Cameroon, 2010–11 | Both | 18–70 | 41.1 ± 11.2 | 47.3 ± 13.7 | 173 | 50 | ≥ 130/85 and on antihypertensive treatment | ATP |
11 | Guehi et al., 2016 [30] | Randomized control trial, Ivory Coast, 2008–14 | Both | 29–42 | NA | NA | 755 | NA | ≥ 140/90 and on antihypertensive treatment | ATP |
12 | Mashinya et al., 2015 [37] | Cross sectional, South Africa, 2013–14 | Both | 44.8 ± 11.8 | NA | NA | 214 | NA | ≥ 140/90 and on antihypertensive treatment | ATP |
13 | Guira et al., 2016 [31] | Cross sectional, Burkina Faso, 2011 | Both | 44.8 + 7.4 | NA | NA | 300 | NA | ≥ 130/85 and on antihypertensive treatment | IDF |
14 | Hirigo et al., 2016 [36] | Cross sectional, Ethiopia, 2013 | Both | 26.5–38 | NA | NA | 185 | NA | ≥ 130/85 and on antihypertensive treatment | IDF, ATP |
15 | Zannou et al., 2009 [28] | Cohort, Benin, 2004–09 | Both | 38.0 ± 9.7 | NA | NA | 79 | NA | ≥ 130/85 and on antihypertensive treatment | IDF |
16 | Muyanja et al., 2016 [39] | Cross sectional, Uganda, NS | Both | 30–43 | NA | NA | 250 | NA | ≥ 140/90 and on antihypertensive treatment | ATP |
17 | Adébayo et al., 2015 [44] | Cross-sectional, Benin, NS | Both | 40,7 ± 9,71 | NA | NA | 244 | NA | ≥130/85 and on antihypertensive treatment | Other |
18 | Sawadogo et al., 2005 [43] | Cross sectional, Burkina Faso, 2011 | Both | 41.4 ± 8.8 | NA | NA | 400 | NA | ≥ 140/90 and on antihypertensive treatment | IDF, ATP |